Supplementary file 1_Immunogenicity and safety of co-administered Escherichia coli-produce

A 2026 clinical trial dataset from Zhejiang Province, China, assessing the immunogenicity and safety of co-administering an E. coli-produced bivalent HPV-16/18 vaccine and a hepatitis E vaccine. The study involved 480 women aged 18–25 years, with results including geometric mean concentrations and seroconversion rates. The dataset was authored by Rui Yan and shared under a CC-BY-4.0 license.

Use Cases

• Assessing non-inferiority of vaccine co-administration based on seroconversion rate differences and GMC ratios described in the results.
• Analyzing safety profiles of combined vaccines based on the reported adverse reaction grades and serious adverse events.
• Modeling immune response levels (GMC) for HPV-16, HPV-18, and HEV across different vaccination groups.
• Studying vaccine trial completion rates based on the per-protocol and safety set participant counts.

Strengths

• Includes data from a randomized, multicenter trial conducted at 4 clinical sites.
• Provides specific immunogenicity metrics, including geometric mean concentrations (e.g., 433.16 IU/mL for HPV-16 in the co-administration group) and 100% seroconversion rates.
• Reports safety outcomes for 480 participants with a clear distinction between per-protocol (462) and safety analysis sets.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for specific analytical tasks.
• Data is limited to a specific demographic (women aged 18–25) and geographic region (Zhejiang Province, China).

Provenance

Source

Rui Yan via figshare.

Collection Method

Randomized, multicenter, open-label clinical trial.

Time Range

The trial followed a 0, 1, 6-month vaccination schedule with measurements at months 0 and 7.

Freshness

Last updated 2026-05-29 06:13:08; freshness should be verified.

Geography

Zhejiang Province, China.